Patents by Inventor David Yowe

David Yowe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PCSK9 antagonists
    Patent number: 8710192
    Abstract: The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a (“PCSK9”) and methods of using such antibodies.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: April 29, 2014
    Assignees: IRM LLC, Novartis AG
    Inventors: Sarah Rue, Steve B. Cohen, Jun Li, David Yowe
  • PCSK9 ANTAGONISTS
    Publication number: 20110142849
    Abstract: The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a (“PCSK9”) and methods of using such antibodies.
    Type: Application
    Filed: December 10, 2010
    Publication date: June 16, 2011
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: SARAH RUE, STEVE B. COHEN, JUN LI, DAVID YOWE
  • Novel RGS-containing molecules and uses thereof
    Publication number: 20050153414
    Abstract: Novel RGS polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length RGS proteins, the invention further provides isolated RGS fusion proteins, antigenic peptides, and anti-RGS antibodies. The invention also provides RGS nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an RGS gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: November 15, 2004
    Publication date: July 14, 2005
    Inventors: Martin Hodge, David Yowe
  • RGS-containing molecules and uses thereof
    Patent number: 6830914
    Abstract: Novel RGS polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length RGS proteins, the invention further provides isolated RGS fusion proteins, antigenic peptides, and anti-RGS antibodies. The invention also provides RGS nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an RGS gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: December 14, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Martin R. Hodge, David Yowe
  • Novel RGS-containing molecules and uses thereof
    Publication number: 20020081683
    Abstract: Novel RGS polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length RGS proteins, the invention further provides isolated RGS fusion proteins, antigenic peptides, and anti-RGS antibodies. The invention also provides RGS nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an RGS gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 27, 2001
    Publication date: June 27, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Martin R. Hodge, David Yowe
  • RGS-containing molecules and uses thereof
    Patent number: 6410240
    Abstract: Novel RGS polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length RGS proteins, the invention further provides isolated RGS fusion proteins, antigenic peptides, and anti-RGS antibodies. The invention also provides RGS nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an RGS gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: June 25, 2002
    Assignee: Millenium Pharmaceuticals, Inc.
    Inventors: Martin R. Hodge, David Yowe
  • Molecules of the AIP-related protein family and uses thereof
    Patent number: 6326481
    Abstract: Novel AIP-6 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length AIP-6 proteins, the invention further provides isolated AIP-6 fusion proteins, antigenic peptides and anti-AIP-6 antibodies. The invention also provides AIP-6 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a AIP-6 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 2, 1999
    Date of Patent: December 4, 2001
    Assignee: Millennium Pharmaceuticals. Inc.
    Inventor: David Yowe
  • RGS-containing molecules and uses thereof
    Patent number: 6274362
    Abstract: Novel RGS polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length RGS proteins, the invention further provides isolated RGS fusion proteins, antigenic peptides, and anti-RGS antibodies. The invention also provides RGS nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an RGS gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: February 4, 1999
    Date of Patent: August 14, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Martin R. Hodge, David Yowe